1. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T, Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020 Feb 24;12(1):8
2. Rabi FA, Al Zoubi MS, Kasasbeh GA, Salameh DM, Al-Nasser AD. SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far. Pathogens. 2020 Mar 20;9(3)
3. To KK, Tsang OT, Chik-Yan Yip C, Chan KH, Wu TC, Chan JMC et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis. 2020 Feb 12. pii: ciaa149. doi:
10.1093/cid/ciaa149
4. Anne L, Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, et al. Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. doi: https://doi.org/10.1101/2020.04.16.20067835
5. Shen L, Niu J, Wang C, Huang B, Wang W, Zhu N, Deng Y, Wang H, ye F, Cen S, Tan W4. 2019. High-Throughput Screening and Identification of Ponent Broad-Spectrum Inhibitors of Coronaviruses. J Virol. 2019 May 29;93(12). pii: e00023-19. doi: 10.1128/JVI.00023-19. Print 2019 Jun 15
6. Popkin DL, Zilka S, Dimaano M, Fujioka H, Rackley C, Salata R et al. Cetylpyridinium chloride (CPC) exhibits potent, rapid activity gainst influenza viruses in vitro and in vivo. Pathogens and Immunity. 2017;2(2):253-69
7. Mukherjee PK, Esper F, Buchheit K, Arters K, Adkins I, Ghannoum MA et al. Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections. BMC Infect Dis. 2017 Jan 14;17(1):74